Skip to main content

Table 1 Characteristics at study enrolment of all 32 patients with non-CF bronchiectasis and of the subset of 22 who experienced exacerbations during the study period

From: Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study

  Whole cohort (n = 32) Patients experiencing exacerbations during study period (n = 22)
Age (years), mean (SD) 61 (12) 59 (12)
Female patients, n (%) 27 (84) 19 (86)
Duration of follow up (days), median (IQR) 491 (386,603) 506 (390,648)
Ever smokers, n (%) 10 (31) 6 (27)
Aetiology, n (%) Post-infectious: 16 (50) Post-infectious: 13 (59)
Idiopathic: 11 (34) Idiopathic: 5 (23)
Rheumatological: 2 (6) Rheumatological: 1 (4)
Other: 3 (9) Other: 3 (14)
Bhalla score, mean (SD) 12 (9) 12 (9)
Number of lobes involved, median (IQR) 3.5 (2,5) 3.5 (2,5)
BSI score, median (IQR) 8.5 (4,12.8) 9 (4.5,11.3)
Severity (BSI classification), n (%) Mild: 9 (28) Mild: 6 (27)
Moderate: 8 (22) Moderate: 4 (18)
Severe: 15 (50) Severe: 12 (55)
Self-reported exacerbation frequency in previous year, median (IQR) 3 (2,5.8) 3 (2.3,6)
Asthma diagnosis, n (%) 7 (22) 6 (27)
Previous pseudomonas on sputum culture, n (%) 7 (22) 5 (23)
Previous hospitalisation, n (%) 9 (28) 8 (36)
Treatment details (all given as n (%))
Short-acting inhaled bronchodilator 13 (41) 10 (45)
Long-acting inhaled bronchodilator 12 (38) 8 (36)
Inhaled corticosteroid use 16 (50) 11 (50)
Long term macrolide therapy, n (%) 2 (6) 2 (9)
Lung function measurements: (all given as mean (SD))
FEV1(L), mean (SD) 1.96 (0.90) 2.02 (0.95)
FEV1% predicted (SD) 78 (26) 76 (28)
FEV1/FVC ratio, (SD) 0.71 (0.15) 0.71 (0.17)
Stable PEFR (L/min), (SD) 334 (104) 337 (110)
PEFR variability, % best (see text) 12.4 (8.2) 13.8 (9.4)
SGRQ and CAT scores (all given as mean (SD))
Symptoms 48.8 (24.3) 50.2 (26.1)
Activity 40.3 (27.8) 41.8 (27.7)
Impact 27.2 (16.5) 29.4 (14.9)
Total SGRQ score 34.8 (18.1) 37.6 (16.9)
CAT score 16.6 (7.0) 17.2 (7.1)